clofibric acid has been researched along with Atherogenesis in 36 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe." | 4.84 | [Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. ( Balcerak, M; Broncel, M; Chojnowska-Jezierska, J, 2007) |
| "MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids." | 4.84 | Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007) |
| "Vascular complications associated with type 2 diabetes confer significant morbidity and mortality." | 2.44 | Atherosclerosis in type 2 diabetes: a role for fibrate therapy? ( Steiner, G, 2007) |
| "The metabolic syndrome is defined as the clustering of cardiovascular risk factors, such as glucose intolerance, hyperinsulinemia, dyslipidemia, coagulation disturbances and hypertension." | 2.43 | Therapeutical effects of PPAR agonists assessed by biomarker modulation. ( Chinetti-Gbaguidi, G; Fruchart, JC; Staels, B, 2005) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "The demography of dyslipidemia has changed towards a more complex atherogenic dyslipidemia involving increased levels of LDL cholesterol, in particular highly atherogenic small dense particles, hypertriglyceridemia and low HDL cholesterol, together with increased levels of markers of inflammation, thrombogenesis and endothelial dysfunction." | 1.35 | [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. ( De Backer, G; Ducobu, J; Hermans, M; Kartounian, J; Legat, P; Maes, M; Scheen, AJ; Van Gaal, L; Velkeniers, B, 2009) |
| "Since atherosclerosis is now regarded as an inflammatory disease and those inflammatory cells play critical important roles in the initiation and development of atherosclerosis, we hypothesize that anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects." | 1.33 | Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects. ( Ye, HJ; Zhao, SP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (91.67) | 29.6817 |
| 2010's | 3 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Paragh, G | 1 |
| Harangi, M | 1 |
| László, M | 1 |
| White, CR | 1 |
| Datta, G | 1 |
| Zhang, Z | 1 |
| Gupta, H | 1 |
| Garber, DW | 1 |
| Mishra, VK | 1 |
| Palgunachari, MN | 1 |
| Handattu, SP | 1 |
| Chaddha, M | 1 |
| Anantharamaiah, GM | 1 |
| Zambon, A | 1 |
| Marchiori, M | 1 |
| Manzato, E | 1 |
| Cardenas, GA | 1 |
| Lavie, CJ | 1 |
| Cardenas, V | 1 |
| Milani, RV | 1 |
| McCullough, PA | 1 |
| Avis, HJ | 1 |
| Vissers, MN | 1 |
| Wijburg, FA | 1 |
| Kastelein, JJ | 1 |
| Hutten, BA | 1 |
| Merkel, M | 1 |
| Sica, DA | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Cybulska, B | 1 |
| Ducobu, J | 2 |
| Scheen, AJ | 1 |
| Legat, P | 1 |
| De Backer, G | 1 |
| Van Gaal, L | 2 |
| Velkeniers, B | 2 |
| Kartounian, J | 1 |
| Maes, M | 1 |
| Hermans, M | 2 |
| Pöss, J | 1 |
| Böhm, M | 1 |
| Laufs, U | 1 |
| Judge, EP | 1 |
| Phelan, D | 1 |
| O'Shea, D | 1 |
| Rubenfire, M | 1 |
| Brook, RD | 1 |
| Rosenson, RS | 1 |
| Meyers, CD | 1 |
| Kashyap, ML | 1 |
| Sampietro, T | 1 |
| Bigazzi, F | 1 |
| Dal Pino, B | 1 |
| Puntoni, M | 1 |
| Bionda, A | 1 |
| Camejo, G | 1 |
| Candido, R | 1 |
| Zanetti, M | 1 |
| Han, SH | 1 |
| Quon, MJ | 1 |
| Koh, KK | 1 |
| Halabi, CM | 1 |
| Sigmund, CD | 1 |
| Ye, HJ | 1 |
| Zhao, SP | 1 |
| Chinetti-Gbaguidi, G | 1 |
| Fruchart, JC | 2 |
| Staels, B | 1 |
| Shaish, A | 1 |
| Harari, A | 1 |
| Hananshvili, L | 1 |
| Cohen, H | 1 |
| Bitzur, R | 1 |
| Luvish, T | 1 |
| Ulman, E | 1 |
| Golan, M | 1 |
| Ben-Amotz, A | 1 |
| Gavish, D | 1 |
| Rotstein, Z | 1 |
| Harats, D | 1 |
| Calkin, AC | 1 |
| Allen, TJ | 1 |
| Duriez, P | 1 |
| Shetty, C | 1 |
| Balasubramani, M | 1 |
| Capps, N | 1 |
| Milles, J | 1 |
| Ramachandran, S | 1 |
| Kostner, KM | 1 |
| Kostner, GM | 1 |
| Broncel, M | 2 |
| Balcerak, M | 1 |
| Chojnowska-Jezierska, J | 1 |
| Cheng, AY | 1 |
| Leiter, LA | 1 |
| Jacobson, TA | 1 |
| Miller, M | 1 |
| Schaefer, EJ | 1 |
| Wójcicka, G | 1 |
| Jamroz-Wiśniewska, A | 1 |
| Horoszewicz, K | 1 |
| Bełtowski, J | 1 |
| Steiner, G | 1 |
| Kuusisto, J | 1 |
| Andrulionyte, L | 1 |
| Laakso, M | 1 |
| Tenenbaum, A | 1 |
| Fisman, EZ | 1 |
| Motro, M | 1 |
| Adler, Y | 1 |
| Brinton, EA | 1 |
| Scheen, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Pulse Varieties on Blood Vessel Function in Individuals With Peripheral Artery Disease (PAD)[NCT01382056] | 62 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease[NCT00755677] | Early Phase 1 | 26 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Lentils as a Functional Food to Improve Glucose Tolerance and Decrease Cardiovascular Disease Risk in Hypercholesterolemic Overweight Individuals[NCT01562171] | 102 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for clofibric acid and Atherogenesis
| Article | Year |
|---|---|
[New trends in lipidology: the increasing role of HDL-cholesterol].
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Pr | 2008 |
HDL therapy for cardiovascular diseases: the road to HDL mimetics.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Pr | 2008 |
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; C | 2008 |
The use of lipid-lowering drug therapy in children and adolescents.
Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Chole | 2009 |
[Diabetic dyslipoproteinemia: beyond LDL].
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy | 2009 |
Fibrate therapy and renal function.
Topics: Animals; Atherosclerosis; Clofibric Acid; Creatinine; Glomerular Filtration Rate; Humans; Kidney; Tr | 2009 |
[Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Clofibric Acid; Drug Therapy, Combination; Dyslipi | 2005 |
[HDL and CETP in atherogenesis].
Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, | 2010 |
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus.
Topics: Atherosclerosis; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combinatio | 2010 |
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combinatio | 2010 |
Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
Topics: Amides; Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Carrier Proteins; Cho | 2005 |
HDL: the 'new' target of cardiovascular medicine.
Topics: Animals; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Homeostasis; Humans; Hypolipoproteinemia | 2006 |
Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Blood Coagulation Factors; Clofibric Acid | 2005 |
Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.
Topics: Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Huma | 2005 |
Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
Topics: Alkanesulfonates; Animals; Atherosclerosis; Clinical Trials as Topic; Clofibric Acid; Humans; Hypert | 2005 |
Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Topics: Animals; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Clofibric Acid; Humans; Inflammation; | 2005 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atherosclerosis | 2006 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
[Fibrate in lipid metabolism disorders].
Topics: Animals; Atherosclerosis; Clofibric Acid; Diabetes Complications; Humans; Hypolipidemic Agents; Lipi | 2007 |
[Fibrates and markers of inflammation].
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; | 2007 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric | 2007 |
PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid | 2008 |
Hypertriglyceridemia and cardiovascular risk reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu | 2007 |
Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.
Topics: Alzheimer Disease; Atherosclerosis; Cholesterol; Clofibric Acid; Diabetes Mellitus; DNA-Binding Prot | 2007 |
Atherosclerosis in type 2 diabetes: a role for fibrate therapy?
Topics: Atherosclerosis; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hydroxymethylglut | 2007 |
Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Clofib | 2007 |
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Topics: Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Dysli | 2008 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D | 2008 |
Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
Topics: Atherosclerosis; Belgium; Clofibric Acid; Dyslipidemias; Humans; Hypolipidemic Agents; Morbidity; Ri | 2008 |
1 trial available for clofibric acid and Atherogenesis
| Article | Year |
|---|---|
9-cis beta-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients.
Topics: Adult; Aged; Animals; Apolipoprotein A-I; Atherosclerosis; beta Carotene; Chlorophyta; Cholesterol, | 2006 |
6 other studies available for clofibric acid and Atherogenesis
| Article | Year |
|---|---|
Bibliography. Current world literature. HDL cholesterol.
Topics: Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Humans; Hypo | 2008 |
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].
Topics: Atherosclerosis; Bradykinin; Cannabinoid Receptor Antagonists; Cannabinoids; Cardiovascular Diseases | 2008 |
[Place of fibrates for the treatment of patients with atherogenic dyslipidemia].
Topics: Atherosclerosis; Clinical Trials as Topic; Clofibric Acid; Dyslipidemias; Humans; Hydroxymethylgluta | 2009 |
Differential antiatherogenic effects of PPARalpha versus PPARgamma agonists: should we be surprised?
Topics: Animals; Atherosclerosis; Clofibric Acid; Humans; Hypoglycemic Agents; PPAR alpha; PPAR gamma | 2005 |
Anti-atherogenic properties of fibrates may be largely due to their anti-inflammatory effects.
Topics: Adipocytes; Anti-Inflammatory Agents; Atherosclerosis; Clofibric Acid; Endothelial Cells; Humans; In | 2006 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type | 2007 |